CSIMarket



Worst Performing Stocks In Major Pharmaceutical Preparations Industry During The Previous 90 Days



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares declined by -2.25% on average, in Major Pharmaceutical Preparations Industry during the previous 90 days.

Here are the Worst performing stocks in Major Pharmaceutical Preparations Industry.




ALLR

$0.4412

$-7.3348 -94.33%
Last 90 Days


ALLR

$0.4412

$-7.3348 -94.33%



Allarity Therapeutics Inc

Allarity Therapeutics Inc shares dropped -94.33% during the previous 90 days.


Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.055 mill. $ - mill. $ -20.698 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.055 mill.


$ - mill.


$ -20.698 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SBFM

$0.3032

$-5.0068 -94.29%
Last 90 Days


SBFM

$0.3032

$-5.0068 -94.29%



Sunshine Biopharma Inc

Sunshine Biopharma Inc stock dropped -94.29% during the previous 90 days.


Sunshine Biopharma Inc is a pharmaceutical company that focuses on developing and commercializing drugs for the treatment of cancer and other diseases. They utilize their expertise in drug discovery and development to create innovative treatments that target specific molecular targets in order to deliver more effective and personalized therapies for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.002 mill. $ 26.740 mill. $ -4.087 mill. 0 mill. - Y/Y 54.09 %
Market Cap. Revenues TTM Net Income TTM

$ 0.002 mill.


$ 26.740 mill.


$ -4.087 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 54.09 %


MRQ Y/Y - %



AVTE

$1.65

$-22.4900 -93.16%
Last 90 Days


AVTE

$1.65

$-22.4900 -93.16%



Aerovate Therapeutics Inc

Aerovate Therapeutics Inc shares declined -93.16% during the previous 90 days.


Aerovate Therapeutics Inc*s business model is focused on developing and commercializing innovative therapeutic solutions for respiratory diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 45.607 mill. $ - mill. $ -72.097 mill. 28 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 45.607 mill.


$ - mill.


$ -72.097 mill.

Employees Shares Outstanding P/E

10


28 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AMPE

$0.1444

$-1.5756 -91.60%
Last 90 Days


AMPE

$0.1444

$-1.5756 -91.60%



Ampio Pharmaceuticals inc

Ampio Pharmaceuticals Inc stock dropped -91.60% during the previous 90 days.


Ampio Pharmaceuticals Inc is a biopharmaceutical company primarily focused on the development of therapies for debilitating diseases. Their business model revolves around identifying unmet medical needs and developing innovative drug candidates to address these needs. They aim to create value through successful clinical development and commercialization of their products, ultimately benefiting patients and generating revenue for the company.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.117 mill. $ - mill. $ -8.632 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.117 mill.


$ - mill.


$ -8.632 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GLYC

$0.2375

$-2.3825 -90.94%
Last 90 Days


GLYC

$0.2375

$-2.3825 -90.94%



Glycomimetics Inc

Glycomimetics Inc stock dropped -90.94% during the previous 90 days.


Glycomimetics Inc is a biopharmaceutical company that utilizes its expertise in carbohydrate chemistry to develop novel drug candidates. Their business model involves researching and developing proprietary glycomimetic compounds that can target specific disease pathways. They then collaborate with pharmaceutical partners to further develop and commercialize these potential therapeutics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 15.309 mill. $ - mill. $ 0.000 mill. 64 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 15.309 mill.


$ - mill.


$ 0.000 mill.

Employees Shares Outstanding P/E

-


64 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VINC

$0.6461

$-5.8039 -89.98%
Last 90 Days


VINC

$0.6461

$-5.8039 -89.98%



Vincerx Pharma Inc

Vincerx Pharma Inc shares declined -89.98% during the previous 90 days.


Vincerx Pharma Inc*s business model is focused on developing and commercializing novel small molecule drugs for the treatment of cancer. They aim to leverage their scientific expertise and collaborations to identify and advance promising drug candidates, ultimately providing innovative therapies to patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13.827 mill. $ - mill. $ -38.245 mill. 21 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 13.827 mill.


$ - mill.


$ -38.245 mill.

Employees Shares Outstanding P/E

-


21 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



EFTR

$1.24

$-9.9100 -88.88%
Last 90 Days


EFTR

$1.24

$-9.9100 -88.88%



Effector Therapeutics Inc

Effector Therapeutics Inc shares declined -88.88% during the previous 90 days.


Effector Therapeutics Inc is a biotech company focused on developing and commercializing effective cancer treatments.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.064 mill. $ - mill. $ -35.941 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 3.064 mill.


$ - mill.


$ -35.941 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VAXX

$0.0924

$-0.6808 -88.05%
Last 90 Days


VAXX

$0.0924

$-0.6808 -88.05%



Vaxxinity Inc

Vaxxinity Inc shares dropped -88.05% during the previous 90 days.


Vaxxinity Inc is a company that operates on a business model that focuses on the development and distribution of vaccines.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11.690 mill. $ - mill. $ -56.934 mill. 127 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 11.690 mill.


$ - mill.


$ -56.934 mill.

Employees Shares Outstanding P/E

-


127 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AEON

$1.55

$-10.8500 -87.50%
Last 90 Days


AEON

$1.55

$-10.8500 -87.50%



Aeon Biopharma inc

Aeon Biopharma Inc stock went down -87.50% during the previous 90 days.


Aeon Biopharma Inc.*s business model focuses on the development and commercialization of biopharmaceutical products, emphasizing innovation and collaboration for the advancement of healthcare.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 95.127 mill. $ - mill. $ 4.825 mill. 61 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 95.127 mill.


$ - mill.


$ 4.825 mill.

Employees Shares Outstanding P/E

-


61 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y 451.84 %



SPRB

$0.6529

$-4.3071 -86.84%
Last 90 Days


SPRB

$0.6529

$-4.3071 -86.84%



Spruce Biosciences Inc

Spruce Biosciences Inc shares declined -86.84% during the previous 90 days.


Spruce Biosciences Inc*s business model focuses on developing and commercializing novel therapies for rare endocrine disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 26.580 mill. $ 7.202 mill. $ -49.114 mill. 41 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 26.580 mill.


$ 7.202 mill.


$ -49.114 mill.

Employees Shares Outstanding P/E

-


41 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CNSP

$2.9

$-18.7450 -86.60%
Last 90 Days


CNSP

$2.9

$-18.7450 -86.60%



Cns Pharmaceuticals Inc

Cns Pharmaceuticals Inc shares dropped -86.60% during the previous 90 days.


CNS Pharmaceuticals Inc*s business model focuses on developing innovative solutions and treatments for central nervous system diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 25.267 mill. $ 0.034 mill. $ -17.464 mill. 9 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 25.267 mill.


$ 0.034 mill.


$ -17.464 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



APVO

$0.6101

$-3.4599 -85.01%
Last 90 Days


APVO

$0.6101

$-3.4599 -85.01%



Aptevo Therapeutics Inc

Aptevo Therapeutics Inc stock went down -85.01% during the previous 90 days.


Aptevo Therapeutics Inc operates as a biotechnology company that focuses on the development of novel oncology and hematology therapeutics. The company primarily generates revenue through the sale of its products and potential collaborations with other pharmaceutical companies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.174 mill. $ - mill. $ -16.151 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.174 mill.


$ - mill.


$ -16.151 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MRNS

$1.45

$-7.8300 -84.38%
Last 90 Days


MRNS

$1.45

$-7.8300 -84.38%



Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc shares went down -84.38% during the previous 90 days.


Marinus Pharmaceuticals Inc operates on a business model centered around developing and commercializing innovative therapeutics for rare neurological disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 82.435 mill. $ 31.478 mill. $ -138.305 mill. 57 mill. - Y/Y 7.22 %
Market Cap. Revenues TTM Net Income TTM

$ 82.435 mill.


$ 31.478 mill.


$ -138.305 mill.

Employees Shares Outstanding P/E

-


57 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 7.22 %


MRQ Y/Y - %



VRPX

$0.7591

$-3.2609 -81.12%
Last 90 Days


VRPX

$0.7591

$-3.2609 -81.12%



Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals Inc stock dropped -81.12% during the previous 90 days.


Virpax Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing innovative non-opioid products to address the unmet needs in pain management. Their business model revolves around research, development, and commercialization of these non-opioid solutions to provide effective and safe pain relief options for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.889 mill. $ - mill. $ -13.615 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.889 mill.


$ - mill.


$ -13.615 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MGNX

$4.29

$-13.3100 -75.63%
Last 90 Days


MGNX

$4.29

$-13.3100 -75.63%



Macrogenics Inc

Macrogenics Inc stock dropped -75.63% during the previous 90 days.


Macrogenics Inc is a biopharmaceutical company that focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer and autoimmune diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 267.226 mill. $ 43.357 mill. $ -23.239 mill. 62 mill. - Y/Y -62.83 %
Market Cap. Revenues TTM Net Income TTM

$ 267.226 mill.


$ 43.357 mill.


$ -23.239 mill.

Employees Shares Outstanding P/E

423


62 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -62.83 %


MRQ Y/Y - %



TFFP

$1.93

$-5.8800 -75.29%
Last 90 Days


TFFP

$1.93

$-5.8800 -75.29%



Tff Pharmaceuticals Inc

Tff Pharmaceuticals Inc stock dropped -75.29% during the previous 90 days.


TFF Pharmaceuticals Inc*s business model revolves around developing and commercializing novel drug therapies using its Thin Film Freezing (TFF) technology, which enhances the solubility and stability of drugs for improved delivery and patient outcomes. They collaborate with pharmaceutical and biotechnology companies to enhance their existing drug compounds and expand their market potential through licensing and partnership agreements.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.662 mill. $ 0.970 mill. $ -13.704 mill. 2 mill. - Y/Y 738.32 %
Market Cap. Revenues TTM Net Income TTM

$ 3.662 mill.


$ 0.970 mill.


$ -13.704 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 738.32 %


MRQ Y/Y - %



PRFX

$0.499

$-1.5010 -75.05%
Last 90 Days


PRFX

$0.499

$-1.5010 -75.05%



Painreform Ltd

Painreform Ltd shares dropped -75.05% during the previous 90 days.


Painreform Ltd operates under a business model focused on developing and commercializing innovative pharmaceutical solutions for pain management. Their approach involves creating novel drug formulations and delivery systems to improve the efficacy, safety, and patient experience in treating acute and chronic pain.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5.320 mill. $ - mill. $ -8.792 mill. 11 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5.320 mill.


$ - mill.


$ -8.792 mill.

Employees Shares Outstanding P/E

-


11 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GRI

$0.2201

$-0.6249 -73.95%
Last 90 Days


GRI

$0.2201

$-0.6249 -73.95%



Gri Bio Inc

Gri Bio Inc stock declined -73.95% during the previous 90 days.


Gri Bio Inc*s business model focuses on providing innovative biotechnology solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.908 mill. $ - mill. $ -12.528 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.908 mill.


$ - mill.


$ -12.528 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



IMRX

$1.535

$-4.3200 -73.78%
Last 90 Days


IMRX

$1.535

$-4.3200 -73.78%



Immuneering Corporation

Immuneering Corporation stock went down -73.78% during the previous 90 days.


Immuneering Corp operates on a business model that harnesses the power of big data in the field of biomedicine. Through their proprietary technologies, they analyze vast amounts of biological data to gain insights into disease mechanisms, drug discovery, and patient care. They leverage their expertise to provide pharmaceutical companies and healthcare organizations with actionable information for accelerating the development of new therapeutics and improving clinical outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 45.083 mill. $ - mill. $ -54.175 mill. 29 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 45.083 mill.


$ - mill.


$ -54.175 mill.

Employees Shares Outstanding P/E

11


29 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ATXI

$3.56

$-9.5575 -72.86%
Last 90 Days


ATXI

$3.56

$-9.5575 -72.86%



Avenue Therapeutics Inc

Avenue Therapeutics Inc stock declined -72.86% during the previous 90 days.


Avenue Therapeutics Inc is a pharmaceutical company that focuses on the development and commercialization of intravenous (IV) opioids for acute pain management. They aim to address the needs of the hospital-based market by providing innovative and effective IV pain medications. Through research, clinical trials, and partnerships with healthcare providers, Avenue Therapeutics Inc strives to improve healthcare outcomes for patients suffering from acute pain conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.027 mill. $ - mill. $ -7.235 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.027 mill.


$ - mill.


$ -7.235 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HUGE

$0.2099

$-0.5491 -72.35%
Last 90 Days


HUGE

$0.2099

$-0.5491 -72.35%



Fsd Pharma Inc

Fsd Pharma Inc stock went down -72.35% during the previous 90 days.


Fsd Pharma Inc*s business model is centered around the development and production of pharmaceutical-grade cannabis products. The company aims to leverage its in-house cultivation facility, research and development capabilities, and strategic partnerships to create innovative cannabis-based therapies for various medical conditions. Fsd Pharma focuses on pursuing licensing and acquisition opportunities to expand its presence in the global cannabis market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ 4.556 mill. $ -17.902 mill. - mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ 4.556 mill.


$ -17.902 mill.

Employees Shares Outstanding P/E

-


- mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



OVID

$0.7896

$-2.0404 -72.10%
Last 90 Days


OVID

$0.7896

$-2.0404 -72.10%



Ovid Therapeutics Inc

Ovid Therapeutics Inc shares went down -72.10% during the previous 90 days.


Ovid Therapeutics Inc*s business model is focused on developing and commercializing innovative medicines for the treatment of rare neurological disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 55.838 mill. $ 0.474 mill. $ -50.677 mill. 71 mill. - Y/Y 123.70 %
Market Cap. Revenues TTM Net Income TTM

$ 55.838 mill.


$ 0.474 mill.


$ -50.677 mill.

Employees Shares Outstanding P/E

51


71 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 123.70 %


MRQ Y/Y - %



PTPI

$0.42

$-1.0700 -71.81%
Last 90 Days


PTPI

$0.42

$-1.0700 -71.81%



Petros Pharmaceuticals inc

Petros Pharmaceuticals Inc stock went down -71.81% during the previous 90 days.


Petros Pharmaceuticals Inc is a pharmaceutical company that operates on a business model focused on the research, development, and commercialization of innovative drugs and therapeutics. They strive to bring new solutions to market by leveraging their expertise in various therapeutic areas, ultimately aiming to improve patient outcomes and well-being.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.890 mill. $ 2.810 mill. $ -32.173 mill. 2 mill. - Y/Y 2,431.22 %
Market Cap. Revenues TTM Net Income TTM

$ 0.890 mill.


$ 2.810 mill.


$ -32.173 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 2,431.22 %


MRQ Y/Y - %



EQ

$0.7166

$-1.8134 -71.68%
Last 90 Days


EQ

$0.7166

$-1.8134 -71.68%



Equillium Inc

Equillium Inc stock dropped -71.68% during the previous 90 days.


Equillium Inc operates on a business model that focuses on developing and commercializing novel treatments for immune and inflammatory disorders by leveraging their expertise in immunology and translational science. They aim to address unmet medical needs through the discovery and development of therapies targeting specific immune pathways.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 24.994 mill. $ 42.632 mill. $ -8.220 mill. 35 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 24.994 mill.


$ 42.632 mill.


$ -8.220 mill.

Employees Shares Outstanding P/E

18,000


35 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CARA

$0.2546

$-0.6254 -71.07%
Last 90 Days


CARA

$0.2546

$-0.6254 -71.07%



Cara Therapeutics inc

Cara Therapeutics Inc shares went down -71.07% during the previous 90 days.


Cara Therapeutics Inc operates under a biotechnology business model focused on developing and commercializing innovative therapeutics to address unmet medical needs, particularly in the field of pruritus and pain management. Their approach involves leveraging their proprietary drug development technology to target specific receptors relevant to these conditions and developing novel pharmaceutical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13.898 mill. $ 16.938 mill. $ -122.544 mill. 55 mill. - Y/Y -65.37 %
Market Cap. Revenues TTM Net Income TTM

$ 13.898 mill.


$ 16.938 mill.


$ -122.544 mill.

Employees Shares Outstanding P/E

-


55 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -65.37 %


MRQ Y/Y - %



GANX

$1.32

$-3.2400 -71.05%
Last 90 Days


GANX

$1.32

$-3.2400 -71.05%



Gain Therapeutics Inc

Gain Therapeutics Inc shares went down -71.05% during the previous 90 days.


Gain Therapeutics inc*s business model revolves around using cutting-edge technology and innovative approaches to identify and develop small molecules that can effectively target and treat rare genetic diseases, such as lysosomal storage disorders and CNS-related disorders. They aim to leverage their expertise in computational drug design and protein structure analysis to discover potential drug candidates, which can then be developed and commercialized for therapeutic purposes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 23.732 mill. $ - mill. $ -21.144 mill. 18 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 23.732 mill.


$ - mill.


$ -21.144 mill.

Employees Shares Outstanding P/E

-


18 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SPRC

$0.8716

$-2.0384 -70.05%
Last 90 Days


SPRC

$0.8716

$-2.0384 -70.05%



Scisparc Ltd

Scisparc Ltd stock declined -70.05% during the previous 90 days.


Scisparc Ltd operates through a specific business model that focuses on providing innovative technological solutions in a particular industry or market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.309 mill. $ 2.879 mill. $ 5.883 mill. 0 mill. 0.06 Y/Y 113.73 %
Market Cap. Revenues TTM Net Income TTM

$ 0.309 mill.


$ 2.879 mill.


$ 5.883 mill.

Employees Shares Outstanding P/E

-


0 mill.


0.06

Revenue Growth Income Growth

MRQ Y/Y 113.73 %


MRQ Y/Y 126.97 %



NCNA

$2.99

$-6.6250 -68.90%
Last 90 Days


NCNA

$2.99

$-6.6250 -68.90%



Nucana Plc

Nucana Plc stock dropped -68.90% during the previous 90 days.


Nucana Plc is a pharmaceutical company that focuses on developing novel treatments for cancer and other diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6.278 mill. $ - mill. $ -32.021 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6.278 mill.


$ - mill.


$ -32.021 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VSTM

$3.47

$-7.3700 -67.99%
Last 90 Days


VSTM

$3.47

$-7.3700 -67.99%



Verastem Inc

Verastem Inc stock declined -67.99% during the previous 90 days.


Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 93.107 mill. $ - mill. $ -105.516 mill. 27 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 93.107 mill.


$ - mill.


$ -105.516 mill.

Employees Shares Outstanding P/E

73


27 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BMEA

$5.09

$-10.5300 -67.41%
Last 90 Days


BMEA

$5.09

$-10.5300 -67.41%



Biomea Fusion Inc

Biomea Fusion Inc shares dropped -67.41% during the previous 90 days.


Biomea Fusion Inc operates on a business model focused on the development of precision medicine for cancer treatments. They leverage advanced genomic technologies to identify and understand specific gene fusions that drive cancer growth. By developing targeted therapies, they aim to improve patient outcomes and revolutionize cancer treatment.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 181.479 mill. $ - mill. $ -107.685 mill. 36 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 181.479 mill.


$ - mill.


$ -107.685 mill.

Employees Shares Outstanding P/E

33


36 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



PXMD

$0.225

$-0.4650 -67.39%
Last 90 Days


PXMD

$0.225

$-0.4650 -67.39%



Paxmedica Inc

Paxmedica Inc shares went down -67.39% during the previous 90 days.


Paxmedica Inc*s business model revolves around providing innovative solutions and technologies in the healthcare sector.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.669 mill. $ - mill. $ -18.149 mill. 7 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.669 mill.


$ - mill.


$ -18.149 mill.

Employees Shares Outstanding P/E

-


7 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VTYX

$2.75

$-5.6700 -67.34%
Last 90 Days


VTYX

$2.75

$-5.6700 -67.34%



Ventyx Biosciences Inc

Ventyx Biosciences Inc stock went down -67.34% during the previous 90 days.


Ventyx Biosciences Inc is a biotechnology company that follows a research and development-focused business model. It aims to develop innovative biopharmaceutical products and therapeutic solutions by leveraging its expertise in various fields such as genetic engineering, drug discovery, and clinical trials. The company seeks to form strategic partnerships and licensing agreements to accelerate the commercialization of its products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 161.921 mill. $ - mill. $ -181.423 mill. 59 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 161.921 mill.


$ - mill.


$ -181.423 mill.

Employees Shares Outstanding P/E

-


59 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ENLV

$1.39

$-2.7800 -66.67%
Last 90 Days


ENLV

$1.39

$-2.7800 -66.67%



Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd shares dropped -66.67% during the previous 90 days.


Enlivex Therapeutics Ltd*s business model focuses on developing and commercializing novel immune system therapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 25.819 mill. $ - mill. $ -29.068 mill. 19 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 25.819 mill.


$ - mill.


$ -29.068 mill.

Employees Shares Outstanding P/E

-


19 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SNGX

$3.82

$-7.5400 -66.37%
Last 90 Days


SNGX

$3.82

$-7.5400 -66.37%



Soligenix inc

Soligenix Inc stock went down -66.37% during the previous 90 days.


Soligenix Inc. is a biopharmaceutical company that focuses on developing and commercializing products to treat rare diseases. Their business model revolves around leveraging their expertise in developing innovative therapies and securing partnerships and collaborations with academic institutions, government agencies, and other companies to accelerate the development process. Soligenix also strategically seeks funding through grants and licensing deals to support their pipeline and growth initiatives.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 40.191 mill. $ 0.699 mill. $ -7.010 mill. 11 mill. - Y/Y -54.49 %
Market Cap. Revenues TTM Net Income TTM

$ 40.191 mill.


$ 0.699 mill.


$ -7.010 mill.

Employees Shares Outstanding P/E

-


11 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -54.49 %


MRQ Y/Y - %



GNLX

$2.39

$-4.3500 -64.54%
Last 90 Days


GNLX

$2.39

$-4.3500 -64.54%



Genelux Corporation

Genelux Corporation shares declined -64.54% during the previous 90 days.


Genelux Corporation*s business model revolves around the development and commercialization of innovative genetic-based therapies and technologies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 58.302 mill. $ - mill. $ -28.297 mill. 24 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 58.302 mill.


$ - mill.


$ -28.297 mill.

Employees Shares Outstanding P/E

-


24 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ADXS

$0.2625

$-0.4775 -64.53%
Last 90 Days


ADXS

$0.2625

$-0.4775 -64.53%



Ayala Pharmaceuticals Inc

Ayala Pharmaceuticals Inc shares went down -64.53% during the previous 90 days.


Ayala Pharmaceuticals Inc is a biopharmaceutical company focused on developing targeted therapies for patients with rare and aggressive cancers. Their business model revolves around leveraging scientific expertise and strategic partnerships to advance their pipeline of potential treatments and ultimately bring them to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.579 mill. $ - mill. $ -48.072 mill. 6 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.579 mill.


$ - mill.


$ -48.072 mill.

Employees Shares Outstanding P/E

-


6 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ALZN

$0.4

$-0.7200 -64.29%
Last 90 Days


ALZN

$0.4

$-0.7200 -64.29%



Alzamend Neuro Inc

Alzamend Neuro Inc shares went down -64.29% during the previous 90 days.


Alzamend Neuro Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for Alzheimer*s disease and other neurological disorders. Their business model revolves around conducting extensive research and clinical trials to develop groundbreaking treatments that address the underlying causes of these debilitating conditions. With a focus on creating value for patients, healthcare providers, and shareholders, they aim to bring effective therapies to market and improve the quality of life for those affected by neurodegenerative diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.822 mill. $ - mill. $ -12.402 mill. 7 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2.822 mill.


$ - mill.


$ -12.402 mill.

Employees Shares Outstanding P/E

-


7 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MRSN

$2.04

$-3.6000 -63.83%
Last 90 Days


MRSN

$2.04

$-3.6000 -63.83%



Mersana Therapeutics inc

Mersana Therapeutics Inc stock went down -63.83% during the previous 90 days.


Mersana Therapeutics Inc*s business model focuses on developing and commercializing novel antibody-drug conjugates (ADCs) for the treatment of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 247.707 mill. $ 38.298 mill. $ -134.813 mill. 121 mill. - Y/Y 18.50 %
Market Cap. Revenues TTM Net Income TTM

$ 247.707 mill.


$ 38.298 mill.


$ -134.813 mill.

Employees Shares Outstanding P/E

-


121 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 18.50 %


MRQ Y/Y - %



GOSS

$0.5201

$-0.8799 -62.85%
Last 90 Days


GOSS

$0.5201

$-0.8799 -62.85%



Gossamer Bio Inc

Gossamer Bio Inc stock dropped -62.85% during the previous 90 days.


Gossamer Bio Inc operates with a business model focused on the development and commercialization of novel therapies for patients with complex diseases. They leverage extensive scientific expertise and strategic partnerships to identify and advance a diverse pipeline of innovative medicines. Their goal is to deliver transformative therapies that address significant unmet medical needs and improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 117.405 mill. $ - mill. $ -172.580 mill. 226 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 117.405 mill.


$ - mill.


$ -172.580 mill.

Employees Shares Outstanding P/E

62


226 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VERV

$5.27

$-8.6500 -62.14%
Last 90 Days


VERV

$5.27

$-8.6500 -62.14%



Verve Therapeutics Inc

Verve Therapeutics Inc stock went down -62.14% during the previous 90 days.


Verve Therapeutics Inc is a biotechnology company specialized in developing transformative medicines that could permanently prevent cardiovascular diseases through gene editing technology. Their business model revolves around leveraging cutting-edge gene editing techniques to develop novel therapeutics targeting specific genes associated with heart diseases. By utilizing this approach, Verve aims to provide long-term solutions for individuals at risk of cardiovascular ailments, addressing a significant unmet need in the healthcare industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 333.126 mill. $ 7.626 mill. $ -192.801 mill. 63 mill. - Y/Y 235.52 %
Market Cap. Revenues TTM Net Income TTM

$ 333.126 mill.


$ 7.626 mill.


$ -192.801 mill.

Employees Shares Outstanding P/E

-


63 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 235.52 %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com